Board Meeting held today to consider and approve Audited Standalone Financial Results for the Quarter and Year ended on March 31, 2026
KRONOX · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kronox Lab Sciences reported total income of Rs. 10,641.40 Lacs for FY2026, up 3.6% from Rs. 10,272.0 Lacs in FY2025. Revenue from operations grew marginally by ~1% to Rs. 10,122 Lacs. PAT increased 8.66% to Rs. 2,766 Lacs from Rs. 2,545.7 Lacs, driven by higher other income (Rs. 518.4 Lacs vs Rs. 252.6 Lacs) and controlled finance costs. EBITDA margin improved on the back of lower employee and material costs as a proportion of revenue. The company declared a 5% final dividend (Rs. 0.50 per share). The statutory auditor issued an unmodified opinion confirming clean financials.
Solid bottom-line growth with 8.66% PAT increase and clean audit report with no qualifications — a positive signal for shareholders. Minimal revenue growth may limit near-term re-rating potential.